CoChat

Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up‐regulation of neurotrophic factors

Open access
Harrison, Ian F, Crum, William R, Vernon, Anthony C, Dexter, David T · 2015 · British Journal of Pharmacology
Cited by 57

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Background and Purpose: Histone hypoacetylation is associated with P arkinson's disease (PD), due possibly to an imbalance in the activities of enzymes responsible for histone (de)acetylation; correction of which may be neuroprotective/neurorestorative. This hypothesis was tested using the anti‐epileptic drug sodium valproate, a known histone deacetylase inhibitor (HDACI), utilizing a delayed‐start study design in the lactacystin rat model of PD. Experimental Approach: The irreversible proteasome inhibitor lactacystin was unilaterally injected into the substantia nigra of S prague–D awley rats that subsequently received valproate for 28 days starting 7 days after lactacystin lesioning. Longitudinal motor behavioural testing, structural MRI and post‐mortem assessment of nigrostriatal integrity were used to track changes in this model of PD and quantify neuroprotection/restoration. Subsequent cellular and molecular analyses were performed to elucidate the mechanisms underlying valproate's effects. Key Results: Despite producing a distinct pattern of structural re‐modelling in the healthy and lactacystin‐lesioned brain, delayed‐start valproate administration induced dose‐dependent neuroprotection/restoration against lactacystin neurotoxicity, characterized by motor deficit alleviation, attenuation of morphological brain changes and restoration of dopaminergic neurons in the substantia nigra. Molecular analyses revealed that valproate alleviated lactacystin‐induced histone hypoacetylation and induced up‐regulation of brain neurotrophic/neuroprotective factors. Conclusions and Implications: The histone acetylation and up‐regulation of neurotrophic/neuroprotective factors associated with valproate treatment culminate in a neuroprotective and neurorestorative phenotype in this animal model of PD. As valproate induced structural re‐modelling of the brain, further research is required to determine whether valproate represents a viable candidate for disease treatment; however, the results suggest that HDACIs could hold potential as disease‐modifying agents in PD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bph.13208

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 57

Metadata

Authors
Harrison, I. F., Crum, W. R., Vernon, A. C., & Dexter, D. T.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2015-07-08
Volume
172
Issue
16
Pages
4200-4215
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1493714881
Cited by
57
References
8
FWCI
4.25
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up‐regulation of neurotrophic factors. https://app.cochat.ai/papers/10.1111/bph.13208
The paper
Harrison, I. F., Crum, W. R., Vernon, A. C., & Dexter, D. T. (2015). Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up‐regulation of neurotrophic factors. British Journal of Pharmacology. https://doi.org/10.1111/bph.13208

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.